By Deron Hamel The third phase of a study examining the impact of cannabidiol (CBD) on people living with severe, drug-resistant forms of epilepsy will paint a clearer picture as to whether or not the cannabis extract has any side effects, says epilepsy researcher Dr. McIntyre Burnham. Phase 2 of the multi-centre study, which was…
By Deron Hamel Kelly Cvijanovich says she hopes Epilepsy Ontario’s second annual fundraising cruise in support of Summerfest Camp will build upon the success from last year’s inaugural event. Cvijanovich, the cruise committee’s chair, says organizers have commissioned a larger boat for this year’s event and are selling more tickets due to the excellent turnout…
By Deron Hamel Results from an early phase clinical trial suggest that cannabidiol (CBD) may be an effective treatment for stemming the number of seizures for people living with severe, drug-resistant forms of epilepsy, however, randomized controlled trials are needed before conclusions can be drawn on the chemical compound’s effectiveness, says Dr. Elizabeth Donner. While…
Update (July 6, 2015): The acetazolamide shortage has been resolved. Acetazolamide tablets are available again from AA Pharma. The Drug Identification Number or DIN is 00545015. Please note that Acetazolam (Valeant Canada LP) is no longer available, this product has been discontinued. Drug Identification Number or DIN is 00295019. If you need any assistance please let…
Sponsor Image 1
Sponsor Image 2
Sponsor Image 3
Sponsor Image 1
Sponsor Image 2
Sponsor Image 3
